PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
Abstract The combination of atezolizumab plus bevacizumab (atezo/bev) has dramatically changed the treatment landscape of advanced HCC (aHCC), achieving durable responses in some patients. Using single-cell transcriptomics, we characterize the intra-tumoural and peripheral immune context of patients...
Shranjeno v:
| Principais autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Portfolio
2023-11-01
|
| Serija: | Nature Communications |
| Online dostop: | https://doi.org/10.1038/s41467-023-43381-1 |
| Oznake: |
Brez oznak, prvi označite!
|
